Bausch + Lomb Corporation is a global eye health company founded in 1853 that develops and markets a comprehensive portfolio of products across three operating segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment includes contact lenses, lens care solutions, over-the-counter eye drops, and nutritional supplements. The Pharmaceuticals segment comprises prescription eye medications, while the Surgical segment offers intraocular lenses, surgical systems, and devices. Key brands include PreserVision, Ocuvite, Biotrue, Renu, Boston, Artelac, Lumify, and Blink. The company serves patients, consumers, and eye care professionals in multiple countries. Bausch + Lomb is a subsidiary of Bausch Health Companies Inc., which holds a majority stake in the company.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Medical Devices Homepage bausch.com
Sector Healthcare IR page ir.bausch.com
Tags
contact lenses, intraocular lenses, ophthalmic pharmaceuticals, eye surgery, lens care, nutritional supplements, dry eye, age-related macular degeneration, redness relief, eye drops, PreserVision, Ocuvite, Biotrue, Renu, Boston, Artelac, Lumify, Blink, Bausch Health Companies Inc.
Press page —

Metrics

Valuation  
Market cap $ 7.319B
Market cap (USD) $ 7.319B
P/E -66.06
PEG —
P/BV 1.14
P/S 1.35
P/OCF 13.21
P/FCF 29.04
Dividend yield —
Turnover / mcap —
Returns  
ROE -5.6%
ROI -3.1%
ROIC 0.74%
Profit margin -7.1%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y Yes
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) No
Debt/Equity 77.9%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 123
Quality score -12.5%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Revenue 5.101B 4.791B 4.146B 3.768B 3.737B
Net profit -360M -317M -260M 6M 182M
Free cash flow -66M -59M -198M 170M 680M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Share price 17.08 18.06 17.06 15.51 —
Price performance 12m -0.05 0.06 0.1 — —

Filed figures

Figure Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — — 721M 724M 839M 1.03B 1.22B
↳ YoY growth +0.4% +15.9% +22.3% +19.0%
Borrowings, current (USD) — — 0.00 25M 30M 40M 28M
Borrowings, non-current (USD) — — 0.00 2.41B 4.53B 4.74B 5.02B
Lease liabilities (USD) — — 112M 118M 114M 152M 163M
Cash and deposits (USD) 192M 238M 174M 354M 331M 305M 383M
Intangible assets (USD) — — 2.26B 2.06B 3.59B 3.49B 3.28B
Right-of-use assets (USD) — — 112M 119M 114M 151M 160M
Net debt (borrowings + leases - cash) (USD) — — -174M 2.2B 4.35B 4.63B 4.83B
Cash flow detail
Operating cash flow (USD) — 522M 873M 345M -17M 232M 283M
Purchases of property, plant and equipment (USD) — -253M -193M -175M -181M -291M -349M
Purchases of intangible assets (USD) — -6M -16M 0.00 — — —
Change in receivables (cash effect) (USD) — 77M -107M -95M -121M -227M -148M
Change in inventories (cash effect) (USD) — -32M -15M -106M -264M -147M 38M
Change in payables (cash effect) (USD) — -144M 163M 189M 245M 126M 108M
Interest paid (cash effect) (USD) — -3M 0.00 -132M -238M -415M -380M
Income taxes paid (cash effect) (USD) — -57M -53M -83M -64M -91M -59M
Share-based compensation (USD) — 50M 62M 62M 74M 92M 149M
Operating cash flow before change in receivables (USD) — 445M 980M 440M 104M 459M 431M
Free cash flow (OCF - PPE - intangibles) (USD) — 263M 664M 170M -198M -59M -66M
Income detail
Research and development expense (USD) — 253M 271M 307M 324M 343M 371M
↳ 5y CAGR +8.0%
Total comprehensive income (USD) — 143M 49M -211M -236M -446M -150M
Comprehensive income to owners (USD) — 139M 36M -217M -247M -457M -159M
Provision for credit losses (USD) — 0.00 2M 4M 3M 3M 6M
Credit cost ratio (credit losses / average receivables) (%) — — — 0.6% 0.4% 0.3% 0.5%
Reported Feb 22, 2023 Feb 22, 2023 Feb 22, 2023 Feb 22, 2023 Feb 21, 2024 Feb 19, 2025 Feb 18, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

OCTOBER 29, 2026

  • Five-country survey found that self-reported dry eye symptoms were more common than reported health care professional diagnosis

  • Among respondents with self-reported dry eye, many managed their symptoms themselves, delayed seeking professional care and reported a substantial effect on daily life

  • Results highlight opportunities to improve awareness and education among people experiencing dry eye symptoms and to encourage timely assessment and appropriate management

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the publication of results from a multinational survey examining symptoms, interactions with health care professionals (HCPs) and treatment experiences to better understand consumer perspectives on dry eye. The findings showed that self-reported dry eye symptoms were more common than reported HCP diagnosis and highlight opportunities to improve patient awareness, education and timely access to appropriate care.

“Dry eye symptoms are common and are often attributed to behavioral or environmental factors, which may contribute to confusion and delays in seeking professional advice,” said Piotr A. Wozniak, MD, PhD, lead author and refractive surgeon and dry eye specialist at Wzroq Eye Clinic in Warsaw, Poland. “The results from this large, multinational survey showed that self-reported dry eye symptoms are more common than reported health care professional diagnoses, with many respondents experiencing symptoms daily. Respondents reported difficulties with screen use, reading, work productivity and driving, and many said they managed their symptoms themselves, delayed seeking care or did not seek professional care. Overall, these findings highlight the importance of patient and clinician education and timely assessment to support appropriate dry eye management.”

The multinational survey Needs Unmet in Dry Eye: Symptoms, Treatment and Severity (NESTS) was conducted in two parts. Phase I surveyed a general population cohort with 2,580 respondents. Phase II included 2,572 gender-, age- and geography-matched subjects with self-reported dry eye in the United Kingdom, France, Germany, Poland and Saudi Arabia.

Key Findings

Survey findings showed that self-reported dry eye symptoms were more common than reported HCP diagnosis. Across the five countries, 14 – 39% (lowest country response – highest country response) of respondents in the general population cohort (Phase I) reported experiencing dry eye regularly, while 13 – 25% reported an HCP diagnosis of dry eye disease (DED). Additional findings include:

  • Of general population respondents (Phase I), 13 – 26% experienced dry eye symptoms frequently and an additional 33 – 41% experienced them occasionally

  • HCP-diagnosed DED was reported by 13 – 25% of general population (Phase I) and by 39 – 61% of self-reported dry eye respondents (Phase II)

  • Approximately one-third of dry eye respondents in Phase II (17 – 39%) did not know whether they had been diagnosed with aqueous or evaporative dry eye

  • Most dry eye respondents (Phase II) had experienced dry eye symptoms for one to five years (58 – 71%), with 19 – 33% having had symptoms for six or more years

  • Among all dry eye respondents (Phase II), 41 – 58% experienced symptoms daily and a further 28 – 41% experienced symptoms several times a week. Fewer than 5% of dry eye sufferers reported symptoms less often than once a week

  • Approximately one-third (30 – 39%) of respondents’ dry eye (Phase II) had worsened in the previous year, with only 5 – 18% reporting an improvement

  • More than 80% of dry eye respondents (Phase II) had to modify behavior because of their dry eye, primarily by limiting screen time (26 – 48%) and keeping eye drops on hand (35 – 51%)

  • Respondents with dry eye (Phase II) attributed their condition to a variety of behavioral, physiological and environmental causes, with 24 – 35% believing it to be an inevitable part of aging

  • Among dry eye respondents (Phase II) who had ever visited an HCP about dry eye, most reported that they were not currently receiving doctor-directed treatment for dry eye

  • Among those who had consulted an HCP for dry eye, up to one-quarter did not agree that they had received the best available guidance from their current healthcare professional

  • At least 70% of dry eye sufferers (Phase II) had used over-the-counter products at least once, with lubricant eye drops the most popular; however, the biggest concerns with dry eye treatments were the need to use them several times a day (20 – 28%) and that the perceived effect of each instillation did not last long enough (20 – 27%)

Overall, these findings suggest a gap between the frequency of self-reported dry eye symptoms and reported HCP diagnosis. They highlight opportunities for timely assessment, improved patient and clinician education, and more personalized management pathways to address the daily-life burden associated with dry eye.

Methodology

The survey was conducted between February and April 2025 in five countries (respondents in Phase I and II, respectively: UK, 508 and 506; France, 512 and 513; Germany, 507 and 523; Poland, 534 and 521; and Saudi Arabia, 519 and 509). Respondents in both cohorts were adults (aged 18 years or older), with those in the dry eye cohort self-reporting that they experience symptoms of dry eyes on a regular basis. The survey was carried out using an online questionnaire, with defined responses and, where relevant, the opportunity to provide an additional response.

About Dry Eye

Dry eye is a multifactorial condition that can be influenced by lifestyle, medications, hormonal changes, age, environmental factors and comorbidities. It may occur when the eyes do not produce enough tears or when tears evaporate too quickly. Inflammation can play an important role in the development and persistence of dry eye disease. Management options vary according to the underlying causes and severity and may include lifestyle or environmental modifications, over-the-counter eye drops and prescription treatments.

About Bausch + Lomb

Our mission is simple – we help people see better to live better, all over the world. For nearly two centuries we’ve evolved with the changing needs of patients and customers, and our commitment to innovation and improving the standard of care in eye health has never been stronger. From contact lenses to prescription products, over-the-counter options, surgical devices and more, we’re turning bold ideas into better outcomes through passion, perseverance and purpose. Learn more at www.bausch.com and connect with us on Facebook, Instagram, LinkedIn, X and YouTube.

| ©2026 Bausch + Lomb. |

| BLNP.0116.USA.26 |

View source version on businesswire.com: https://www.businesswire.com/news/home/20261029221923/en/

Media:

Caryn Marshall

[email protected]

(908) 493-1381

Source: Bausch + Lomb Corporation

*Historical Archives for Predecessor Entities

X

You are now leaving the Bausch + Lomb Website

The website you are about to visit is not affiliated with Bausch + Lomb Incorporated. Bausch + Lomb is not responsible for the content, format, maintenance, or policies of the website you are about to enter and does not monitor non-affiliated websites for accuracy. Links to non-affiliated websites are provided as a convenience; they do not constitute an endorsement or support of any programs, products, or services associated with the website.

Cancel Continue

OCTOBER 29, 2026

  • Five-country survey found that self-reported dry eye symptoms were more common than reported health care professional diagnosis

  • Among respondents with self-reported dry eye, many managed their symptoms themselves, delayed seeking professional care and reported a substantial effect on daily life

  • Results highlight opportunities to improve awareness and education among people experiencing dry eye symptoms and to encourage timely assessment and appropriate management

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the publication of results from a multinational survey examining symptoms, interactions with health care professionals (HCPs) and treatment experiences to better understand consumer perspectives on dry eye. The findings showed that self-reported dry eye symptoms were more common than reported HCP diagnosis and highlight opportunities to improve patient awareness, education and timely access to appropriate care.

“Dry eye symptoms are common and are often attributed to behavioral or environmental factors, which may contribute to confusion and delays in seeking professional advice,” said Piotr A. Wozniak, MD, PhD, lead author and refractive surgeon and dry eye specialist at Wzroq Eye Clinic in Warsaw, Poland. “The results from this large, multinational survey showed that self-reported dry eye symptoms are more common than reported health care professional diagnoses, with many respondents experiencing symptoms daily. Respondents reported difficulties with screen use, reading, work productivity and driving, and many said they managed their symptoms themselves, delayed seeking care or did not seek professional care. Overall, these findings highlight the importance of patient and clinician education and timely assessment to support appropriate dry eye management.”

The multinational survey Needs Unmet in Dry Eye: Symptoms, Treatment and Severity (NESTS) was conducted in two parts. Phase I surveyed a general population cohort with 2,580 respondents. Phase II included 2,572 gender-, age- and geography-matched subjects with self-reported dry eye in the United Kingdom, France, Germany, Poland and Saudi Arabia.

Key Findings

Survey findings showed that self-reported dry eye symptoms were more common than reported HCP diagnosis. Across the five countries, 14 – 39% (lowest country response – highest country response) of respondents in the general population cohort (Phase I) reported experiencing dry eye regularly, while 13 – 25% reported an HCP diagnosis of dry eye disease (DED). Additional findings include:

  • Of general population respondents (Phase I), 13 – 26% experienced dry eye symptoms frequently and an additional 33 – 41% experienced them occasionally

  • HCP-diagnosed DED was reported by 13 – 25% of general population (Phase I) and by 39 – 61% of self-reported dry eye respondents (Phase II)

  • Approximately one-third of dry eye respondents in Phase II (17 – 39%) did not know whether they had been diagnosed with aqueous or evaporative dry eye

  • Most dry eye respondents (Phase II) had experienced dry eye symptoms for one to five years (58 – 71%), with 19 – 33% having had symptoms for six or more years

  • Among all dry eye respondents (Phase II), 41 – 58% experienced symptoms daily and a further 28 – 41% experienced symptoms several times a week. Fewer than 5% of dry eye sufferers reported symptoms less often than once a week

  • Approximately one-third (30 – 39%) of respondents’ dry eye (Phase II) had worsened in the previous year, with only 5 – 18% reporting an improvement

  • More than 80% of dry eye respondents (Phase II) had to modify behavior because of their dry eye, primarily by limiting screen time (26 – 48%) and keeping eye drops on hand (35 – 51%)

  • Respondents with dry eye (Phase II) attributed their condition to a variety of behavioral, physiological and environmental causes, with 24 – 35% believing it to be an inevitable part of aging

  • Among dry eye respondents (Phase II) who had ever visited an HCP about dry eye, most reported that they were not currently receiving doctor-directed treatment for dry eye

  • Among those who had consulted an HCP for dry eye, up to one-quarter did not agree that they had received the best available guidance from their current healthcare professional

  • At least 70% of dry eye sufferers (Phase II) had used over-the-counter products at least once, with lubricant eye drops the most popular; however, the biggest concerns with dry eye treatments were the need to use them several times a day (20 – 28%) and that the perceived effect of each instillation did not last long enough (20 – 27%)

Overall, these findings suggest a gap between the frequency of self-reported dry eye symptoms and reported HCP diagnosis. They highlight opportunities for timely assessment, improved patient and clinician education, and more personalized management pathways to address the daily-life burden associated with dry eye.

Methodology

The survey was conducted between February and April 2025 in five countries (respondents in Phase I and II, respectively: UK, 508 and 506; France, 512 and 513; Germany, 507 and 523; Poland, 534 and 521; and Saudi Arabia, 519 and 509). Respondents in both cohorts were adults (aged 18 years or older), with those in the dry eye cohort self-reporting that they experience symptoms of dry eyes on a regular basis. The survey was carried out using an online questionnaire, with defined responses and, where relevant, the opportunity to provide an additional response.

About Dry Eye

Dry eye is a multifactorial condition that can be influenced by lifestyle, medications, hormonal changes, age, environmental factors and comorbidities. It may occur when the eyes do not produce enough tears or when tears evaporate too quickly. Inflammation can play an important role in the development and persistence of dry eye disease. Management options vary according to the underlying causes and severity and may include lifestyle or environmental modifications, over-the-counter eye drops and prescription treatments.

About Bausch + Lomb

Our mission is simple – we help people see better to live better, all over the world. For nearly two centuries we’ve evolved with the changing needs of patients and customers, and our commitment to innovation and improving the standard of care in eye health has never been stronger. From contact lenses to prescription products, over-the-counter options, surgical devices and more, we’re turning bold ideas into better outcomes through passion, perseverance and purpose. Learn more at www.bausch.com and connect with us on Facebook, Instagram, LinkedIn, X and YouTube.

| ©2026 Bausch + Lomb. |

| BLNP.0116.USA.26 |

View source version on businesswire.com: https://www.businesswire.com/news/home/20261029221923/en/

Media:

Caryn Marshall

[email protected]

(908) 493-1381

Source: Bausch + Lomb Corporation

*Historical Archives for Predecessor Entities

X

You are now leaving the Bausch + Lomb Website

The website you are about to visit is not affiliated with Bausch + Lomb Incorporated. Bausch + Lomb is not responsible for the content, format, maintenance, or policies of the website you are about to enter and does not monitor non-affiliated websites for accuracy. Links to non-affiliated websites are provided as a convenience; they do not constitute an endorsement or support of any programs, products, or services associated with the website.

Cancel Continue

On October 28, 2026, Nathalie Bernier notified Bausch + Lomb Corporation (the “Company”) of her decision to resign from the Board of Directors of the Company (the “Board”) and from the Science and Technology Committee of the Board, effective at the close of business. In connection with Ms. Bernier’s resignation and entry into a general mutual release of certain claims, the Company has agreed to pay Ms. Bernier prorated cash compensation for her service and to accelerate the vesting, in full, of the outstanding and unvested restricted share unit awards received by Ms. Bernier as part of her 2026 annual grant. The Board does not currently intend to fill the board vacancy created by Ms. Bernier’s resignation. Ms. Bernier’s resignation was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

Prompts

Bausch Lomb Corporation (ticker BLCO), listed in United States.

Company History

Date Change Detail
— Predecessor Predecessor Bausch & Lomb Inc (CIK 10427) filed under its own registration; its figures are on its own company page, not shown here.

ETFs Holding Bausch Lomb Corporation

ETF Weight in ETF Shares Market value As of
MGMT 1.37% 147,837 $ 2.448M Jun 30, 2026
GVLU 0.05% 6,109 $ 127.556K Nov 17, 2026
SHRT 0.01% 87 $ 1,816.56 Nov 17, 2026
DFAX 0.00% 15,182 $ 320.947K Nov 12, 2026
DFIC 0.00% 4,958 $ 104.762K Nov 12, 2026

Securities

Ticker Type Class Market Exchange Last price Price date
BLCO canonical Common share — US nyse 20.48 USD 2026-10-29
BLCO Common share — CA tsx — —